Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study Authors: Chun-Tse Hung, Chen-Yen An, Chi-Won Suk, Ting-Wei Lee, Shun-Hsing Hung Published: 2026 ABSTRACT BackgroundWhile glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promise in improving respiratory outcomes, the comparative effectiveness of dual glucose-dependent insulinotropic polypeptide/GLP-1 RA versus GLP-1 RA alone remains unclear.ObjectiveTo assess the association of tirzepatide versus semaglutide with the risk of asthma exacerbation among patients with asthma and type 2 diabetes (T2D).MethodsData from the TriNetX US Collaborative Network were used. Adults with asthma and T2D who initiated tirzepatide or semaglutide between June 01, 2022, and December 31, 2024, were included. The study period ended on December 1, 2025. The primary outcome was time to first asthma exacerbation over a 12-month follow-up. Secondary outcomes included systemic corticosteroid and short-acting beta-agonist (SABA) use. Propensity score matching was used to balance baseline covariates. Kaplan-Meier curves and Cox regression models were used to estimate comparative effectiveness.ResultsAfter 1:1 matching, 8176 patients were included in each group. The risk of asthma exacerbation was similar between tirzepatide and semaglutide (11.0% vs 11.1%; HR, 1.00; 95% CI, 0.91–1.10). This finding remained consistent across sensitivity and subgroup analyses. For secondary outcomes, tirzepatide was associated with a lower risk of SABA use (HR, 0.92; 95% CI, 0.88–0.96) and a similar risk of systemic corticosteroid use (HR, 1.01; 95% CI, 0.96–1.05) compared with semaglutide.ConclusionAmong patients with asthma and T2D, no difference in the risk of asthma exacerbation between tirzepatide and semaglutide was observed. Further investigation through randomized controlled trials is warranted to clarify the potential role of GLP-1 RA-based therapies in patients with asthma and T2D. Introduction Asthma and type 2 diabetes (T2D) frequently coexist, with approximately 13–16% of patients with asthma also having T2D.1,2 This comorbidity is clinically important because individuals with both conditions experience poorer asthma control, more frequent and severe exacerbations, and greater healthcare utilization than those with asthma alone.1,3 These adverse outcomes are likely driven by shared pathophysiological mechanisms, including metabolic dysregulation and systemic inflammation.1–3 Obesity is a critical mediator in the relationship between asthma and T2D.4,5 Excess adiposity promotes airway hyperresponsiveness, impairs lung mechanics, and induces corticosteroid resistance in patients with asthma.4–7 Moreover, poor glycemic control in T2D exacerbates airway inflammation and increases the risk of asthma exacerbations.6–8 Therefore, antidiabetic medications that target both metabolic dysfunction and glycemic control may improve asthma control in this high-risk population.6–10 Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, have revolutionized T2D management through their glucose-lowering effects and weight reduction.11,12 More recently, tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA, has demonstrated better effectiveness in weight reduction and glycemic control compared with GLP-1 RA monotherapy.12–14 Beyond their metabolic effects, preclinical data suggest that incretin-based therapies may attenuate airway inflammation, reduce bronchial hyperresponsiveness, and decrease levels of proinflammatory cytokines.9,10 Despite the biological plausibility that these novel antidiabetic agents could benefit respiratory health, evidence examining the association between GLP-1–based therapies and asthma exacerbations remains limited. A previous study using the TriNetX database compared tirzepatide and semaglutide among a broader population of patients with asthma and reported differences in asthma-related outcomes, such as obstructive sleep apnea and sleep apnea.15 However, patients with T2D represented a subgroup of that study population.15 Because tirzepatide and semaglutide are primarily prescribed for metabolic indications, restricting the comparison to patients with comorbid asthma and T2D may provide a more clinically relevant assessment and reduce confounding by differences in treatment indication and underlying metabolic risk. Furthermore, it remains unclear whether the greater weight reduction and glycemic improvement associated with tirzepatide translate into a lower risk of asthma exacerbation compared with semaglutide among patients with both asthma and T2D. Given the rapidly increasing use of these agents, there is a critical need to evaluate their comparative effects on respiratory outcomes. This study aimed to assess the association of tirzepatide versus semaglutide with the risk of asthma exacerbation among patients with asthma and T2D. We hypothesized that tirzepatide would be associated with a lower risk of asthma exacerbation than semaglutide. Methods Data Source Electronic health records (EHR) data from the TriNetX US Collaborative Network were used. TriNetX is a federated platform for health research and includes information on medical encounters, demographics, diagnoses, medications, laboratory test results, and procedures.16,17 The US Collaborative Network of TriNetX involves over 65 healthcare organizations in the US, and its data have been proven to align well with the overall demographics of the general US population.17 Study Design and Study Population This was a multicenter retrospective cohort study with a new-user and active-comparator design (Figure 1). Patients aged ≥18 years with asthma and T2D diagnosis who initiated semaglutide or tirzepatide between June 1, 2022, and December 1, 2024, were included. The study period ended on December 1, 2025. The start date of the enrollment was determined based on the US Food and Drug Administration approval of tirzepatide for T2D in May 2022.18 The first prescription date for semaglutide or tirzepatide was defined as the index date. Diagnoses of asthma and T2D were defined as having at least two medical encounters for both conditions one year prior to the index date (baseline period). New users of semaglutide or tirzepatide were defined by individuals who did not use any GLP-1 RAs or GIP/GLP-1 RAs one year before the index date.Figure 1Graphical depiction of the study design. Patients were followed from the index date until the first asthma exacerbation, the end of follow-up, or the end of their health records in TriNetX, whichever occurred first.A timeline diagram of study phases for semaglutide or tirzepatide prescription. Graphical depiction of the study design. Patients were followed from the index date until the first asthma exacerbation, the end of follow-up, or the end of their health records in TriNetX, whichever occurred first. To reduce confounding by indication, patients with type 1 diabetes or gestational diabetes were excluded. Patients with chronic obstructive pulmonary disease (COPD) were also excluded to minimize misclassifications. Lastly, patients with missing values for body mass index (BMI) and hemoglobin A1c (HbA1c) were excluded. These criteria were assessed during the baseline period. Diagnoses were identified using International Classification of Diseases, Tenth Revision (ICD‐10) codes (Supplementary Table 1), and prescriptions were identified using Anatomical Therapeutic Chemical (ATC) and RxNorm codes (Supplementary Table 2). Exposure Patients were grouped as tirzepatide or semaglutide users based on the drug initiated on the index date. Patients were considered exposed if they had at least one prescription record for the respective drug in the TriNetX database. Consistent with the intention-to-treat approach, patients remained in their original exposure group during follow-up regardless of subsequent treatment discontinuation or switching. Outcomes The primary outcome was the time to the first asthma exacerbation, defined as the first occurrence of an asthma exacerbation diagnosis recorded during encounter using prespecified ICD-10 codes (Supplementary Table 1). Secondary outcomes included time to the first prescription of systemic corticosteroids and short-acting beta-agonists (SABA), which were examined as additional asthma-related medication outcomes (Supplementary Table 2). Patients were followed for 12 months from the index date until the first occurrence of outcomes, the end of follow-up, or the end of their health records in TriNetX, whichever came first. Covariates Supplementary Figure 1 presents the directed acyclic graph that guided the selection of covariates. These covariates included demographics (age, sex, and race), current tobacco use, BMI, HbA1c, comorbidities and concomitant medications. Demographics and current tobacco use were assessed on the index date. Laboratory results, comorbidities, and concomitant medications were assessed during the one year before the index date. Comorbidities included hypertension, hyperlipidemia, ischemic heart diseases, heart failure (HF), atrial fibrillation and flutter, cerebral infarction, chronic kidney disease (CKD), obstructive sleep apnea, hypothyroidism, depressive episode, allergic rhinitis, and chronic sinusitis. These comorbidities were included as they are risk factors of asthma exacerbation.6,19,20 Concomitant medications included asthma medications and diabetes medications. Statistical Analysis A 1:1 propensity score matching (PSM) was performed to balance measurable covariates between tirzepatide and semaglutide users. Propensity scores were calculated using a logistic regression model with all covariates, including demographics (age, sex, and race), current tobacco use, BMI, HbA1c, comorbidities, and concomitant asthma and diabetes medications. Tirzepatide versus semaglutide was specified as the dependent variable. The greedy nearest-neighbor matching method with a caliper width of 0.1 pooled standard deviations was applied. Covariate balance was assessed using standardized mean differences (SMDs), with an absolute SMD <0.1 indicating well-balanced. Kaplan-Meier curves with Log rank tests were used to compare event-free probabilities. Cox proportional hazards models were used to evaluate the association of tirzepatide versus semaglutide with asthma exacerbation. Hazard ratios (HRs) and 95% confidence intervals (CIs) were reported. The proportional hazards assumption was assessed using the Schoenfeld residuals test. Statistical significance was determined with two-sided tests (P-value<0.05). Approximately 4% of the study population had missing data on race (Table 1). Missing data was handled by the missing indicator method in TriNetX.16 Missing values were categorized as “unknown” groups, as imputations were not available in the analytic platform.16 All analyses were conducted using built-in analytic tools in TriNetX.Table 1Baseline Characteristics of the Study PopulationBefore PSM (N=36,313)aSMDAfter PSM (N=16,352)aSMDTirzepatide UsersSemaglutide UsersTirzepatide UsersSemaglutide Users(N=8,178)(N=28,135)(N=8,176)(N=8,176)N%N%N%N%DemographicsAge (years), mean (SD)55.112.656.212.90.0955.112.655.113.0<0.01Female595272.820,47672.8<0.01595172.8596172.9<0.01Race White570569.817,96363.80.13570369.8576170.50.02 Black or African American155519.0643722.90.10155519.0153718.80.01 Asian2102.68943.20.042102.61962.40.01 Native Hawaiian or Other Pacific Islander580.72660.90.03580.7500.60.01 American Indian or Alaska Native560.72460.90.02560.7570.7<0.01 Other Race2843.511914.20.042843.52763.40.01 Unknown Race3103.811384.00.013103.82993.70.01Current tobacco use1692.17402.60.041692.11581.90.01BMI (kg/m2)<30112813.8468616.70.09112813.8111113.60.01≥30705086.223,44983.30.04704886.2706586.40.01HbA1c<7%442254.115,13253.80.03442054.1449254.90.02≥7%375645.913,00346.20.03375645.9368445.10.02ComorbiditiesHypertension557868.220,06971.30.07557768.2556868.10.00Hyperlipidemia331340.511,61741.30.02331240.5326740.00.01Ischemic heart diseases118414.5429215.30.02118414.5117214.3<0.01Heart failure7749.5290310.30.037749.57789.5<0.01Atrial fibrillation and flutter4675.719076.80.044675.74635.7<0.01Cerebral infarction1852.36862.40.011852.31862.3<0.01Chronic kidney disease97312.0368513.10.0397311.995611.70.01Obstructive sleep apnea258131.6825529.30.05258031.6254531.10.01Hypothyroidism148518.2509418.1<0.01148418.2147618.1<0.01Depressive episode179622.0598221.30.02179522.0179522.00Allergic rhinitis6487.920937.40.026477.95937.30.02Chronic sinusitis5116.215435.50.035096.24795.90.02Concomitant medicationsAsthma medications Inhaled corticosteroids387547.413,65148.50.02387447.4383346.9<0.01 SABA or LABA456055.816,08657.20.03455955.8453655.50.01 Prednisone184122.5630422.4<0.01183922.5181022.10.01 Leukotriene receptor antagonists148618.2507218.0<0.01148518.2147618.1<0.01 Tiotropium1271.65321.90.031271.61261.50.00 Umeclidinium2352.97212.60.022352.92232.70.01 Xanthines650.82130.8<0.01650.8560.7<0.01 Biologics or immunomodulators801.02480.90.01801.0791.00.00Diabetes medications Metformin317538.811,81842.00.06317438.8316238.7<0.01 Insulin217326.6709925.20.03217126.6210325.70.02 Sulfonylureas7839.6323311.50.067839.67238.80.03 Dipeptidyl peptidase-4 inhibitor4966.118396.50.024966.14705.7<0.01 Sodium-glucose co-transporter 2 inhibitor129315.8434015.40.01129115.8125115.30.01Abbreviations: aSMD, absolute standardized mean difference; BMI, body mass index; HbA1c, hemoglobin A1c; LABA, long-acting β2 agonist; PSM, propensity score matching; SABA, short-acting β2 agonist; SD, standard deviation. Table 1Baseline Characteristics of the Study PopulationBefore PSM (N=36,313)aSMDAfter PSM (N=16,352)aSMDTirzepatide UsersSemaglutide UsersTirzepatide UsersSemaglutide Users(N=8,178)(N=28,135)(N=8,176)(N=8,176)N%N%N%N%DemographicsAge (years), mean (SD)55.112.656.212.90.0955.112.655.113.0<0.01Female595272.820,47672.8<0.01595172.8596172.9<0.01Race White570569.817,96363.80.13570369.8576170.50.02 Black or African American155519.0643722.90.10155519.0153718.80.01 Asian2102.68943.20.042102.61962.40.01 Native Hawaiian or Other Pacific Islander580.72660.90.03580.7500.60.01 American Indian or Alaska Native560.72460.90.02560.7570.7<0.01 Other Race2843.511914.20.042843.52763.40.01 Unknown Race3103.811384.00.013103.82993.70.01Current tobacco use1692.17402.60.041692.11581.90.01BMI (kg/m2)<30112813.8468616.70.09112813.8111113.60.01≥30705086.223,44983.30.04704886.2706586.40.01HbA1c<7%442254.115,13253.80.03442054.1449254.90.02≥7%375645.913,00346.20.03375645.9368445.10.02ComorbiditiesHypertension557868.220,06971.30.07557768.2556868.10.00Hyperlipidemia331340.511,61741.30.02331240.5326740.00.01Ischemic heart diseases118414.5429215.30.02118414.5117214.3<0.01Heart failure7749.5290310.30.037749.57789.5<0.01Atrial fibrillation and flutter4675.719076.80.044675.74635.7<0.01Cerebral infarction1852.36862.40.011852.31862.3<0.01Chronic kidney disease97312.0368513.10.0397311.995611.70.01Obstructive sleep apnea258131.6825529.30.05258031.6254531.10.01Hypothyroidism148518.2509418.1<0.01148418.2147618.1<0.01Depressive episode179622.0598221.30.02179522.0179522.00Allergic rhinitis6487.920937.40.026477.95937.30.02Chronic sinusitis5116.215435.50.035096.24795.90.02Concomitant medicationsAsthma medications Inhaled corticosteroids387547.413,65148.50.02387447.4383346.9<0.01 SABA or LABA456055.816,08657.20.03455955.8453655.50.01 Prednisone184122.5630422.4<0.01183922.5181022.10.01 Leukotriene receptor antagonists148618.2507218.0<0.01148518.2147618.1<0.01 Tiotropium1271.65321.90.031271.61261.50.00 Umeclidinium2352.97212.60.022352.92232.70.01 Xanthines650.82130.8<0.01650.8560.7<0.01 Biologics or immunomodulators801.02480.90.01801.0791.00.00Diabetes medications Metformin317538.811,81842.00.06317438.8316238.7<0.01 Insulin217326.6709925.20.03217126.6210325.70.02 Sulfonylureas7839.6323311.50.067839.67238.80.03 Dipeptidyl peptidase-4 inhibitor4966.118396.50.024966.14705.7<0.01 Sodium-glucose co-transporter 2 inhibitor129315.8434015.40.01129115.8125115.30.01Abbreviations: aSMD, absolute standardized mean difference; BMI, body mass index; HbA1c, hemoglobin A1c; LABA, long-acting β2 agonist; PSM, propensity score matching; SABA, short-acting β2 agonist; SD, standard deviation. Baseline Characteristics of the Study Population Abbreviations: aSMD, absolute standardized mean difference; BMI, body mass index; HbA1c, hemoglobin A1c; LABA, long-acting β2 agonist; PSM, propensity score matching; SABA, short-acting β2 agonist; SD, standard deviation. Sensitivity Analyses Two sensitivity analyses were conducted to test the robustness of the findings. First, the follow-up period was changed to six or eighteen months. Because the metabolic effects of tirzepatide and semaglutide may require a longer duration to translate into respiratory benefits,9,14 the follow-up period was alternatively defined in these analyses. Second, we raised the threshold for identifying new users to two years, ie, patients were included if they had not used any GLP-1 RAs or GIP/GLP-1 RAs two years before the index date. Subgroup Analyses Subgroup analyses were conducted based on: (1) BMI (≥ 30 and <30 kg/m2), (2) HbA1c (≥ 7% and <7%), (3) HF (yes and no), (4) CKD (yes and no), (5) prednisone use at baseline (yes and no), and (6) history of asthma exacerbation (yes and no). Results Figure 2 illustrates the selection of the study population. A total of 455,196 patients with asthma and T2D were identified. Among them, 8178 received tirzepatide and 28,135 received semaglutide, all of whom met the study criteria. After PSM, there were 8176 patients in both groups.Figure 2Flowchart of the selection of study population.Flowchart of study population selection for asthma and type 2 diabetes patients.The flowchart illustrates the selection process of a study population involving adults with asthma and type 2 diabetes enrolled from June 1, 2022, to December 1, 2024, totaling 455,196 individuals. The process is divided into two groups: patients newly initiated on tirzepatide and those on semaglutide. Initially, 15,716 patients were on tirzepatide and 52,959 on semaglutide. Exclusions were made for type 1 or gestational diabetes, chronic obstructive pulmonary disease, missing body mass index values and missing hemoglobin A1c values. After exclusions, 8,178 tirzepatide users and 28,135 semaglutide users were eligible for the study. Flowchart of the selection of study population. Before PSM, tirzepatide users had a higher proportion of White, and a lower proportion of Black or African American compared to semaglutide users (Table 1). After PSM, all characteristics were well-balanced between both groups. After PSM, the mean follow-up duration was 352.2 days for tirzepatide users and 355.4 days for semaglutide users (Supplementary Table 3). Figure 3 presents the results from main and sensitivity analyses. This risk of asthma exacerbation was similar between tirzepatide and semaglutide (HR, 1.00; 95% CI, 0.91–1.10). When the follow-up period was changed to six or eighteen months, the risk of asthma exacerbation remained similar between groups (six months: HR, 0.99; 95% CI, 0.88–1.11; eighteen months: HR, 0.98; 95% CI, 0.91–1.06). Similarly, when the threshold for identifying new users was raised to two years, the risk of asthma exacerbation did not differ between groups (HR, 0.98; 95% CI, 0.89–1.08). The proportional hazards assumption was not violated in the main analysis (χ2=0.577, df=1, P=0.45) or in any sensitivity or subgroup analyses. Results from Kaplan-Meier curves also support these findings (Supplementary Figure 2).Figure 3Risk of asthma exacerbation between tirzepatide and semaglutide among patients with asthma and type 2 diabetes in the matched cohorts (main and sensitivity analyses).A forest plot comparing asthma exacerbation risk between tirzepatide and semaglutide across analyses.A forest plot compares Tirzepatide and Semaglutide. The table shows event rates: Main analysis - Tirzepatide 11.0% (897/8,176), Semaglutide 11.1% (905/8,176). Sensitivity analyses: 6 months - Tirzepatide 7.2% (585/8,176), Semaglutide 7.2% (592/8,176); 18 months - Tirzepatide 13.0% (1,063/8,176), Semaglutide 13.6% (1,115/8,176). New user threshold at two years: Tirzepatide 11.0% (757/6,873), Semaglutide 11.3% (780/6,873). The plot′s right side shows hazard ratios with a reference line at 1, indicating favorability: Main analysis HR 1.00 (0.91, 1.10); 6 months HR 0.99 (0.88, 1.11); 18 months HR 0.98 (0.90, 1.06); two years threshold HR 0.98 (0.89, 1.08). The x-axis ranges from 0.4 to 1.6, with ′Favor tirzepatide′ on the left and ′Favor semaglutide′ on the right.Abbreviations: CI, confidence interval; HR, hazard ratio. Risk of asthma exacerbation between tirzepatide and semaglutide among patients with asthma and type 2 diabetes in the matched cohorts (main and sensitivity analyses). Figure 4 and Supplementary Table 4 show the results from subgroup analyses. Consistent with the main analysis, the risk of asthma exacerbation did not differ between tirzepatide and semaglutide regardless of baseline BMI, HbA1c, HF, CKD, prednisone use, and history of asthma exacerbation.Figure 4Risk of asthma exacerbation between tirzepatide and semaglutide among patients with asthma and type 2 diabetes in the matched cohorts (subgroup analyses). As TriNetX is a real-time updating data platform, patient records are continuously updated with new medical encounters or changes in eligibility. Subgroup analyses involved filtering the original cohort (pre-matching) by subgroup criteria and then re-performing 1:1 propensity score matching, which may result in slight differences in patient numbers compared to the main analysis due to data updates at the time of each query.A forest plot of asthma exacerbation risk comparing tirzepatide versus semaglutide across subgroups.Subgroup analyses are presented in a forest plot with a central reference line at a hazard ratio of 1. The x-axis ranges from 0.4 to 1.6. Subgroups include BMI (<30, greater than or equal to 30), hemoglobin A1c (<7%, greater than or equal to 7%), baseline heart failure (yes, no), chronic kidney disease (yes, no), prednisone use (yes, no) and asthma exacerbation history (yes, no). Each subgroup has a point estimate with a 95% confidence interval. Hazard ratios with confidence intervals are: 0.93 (0.72, 1.22); 1.00 (0.91, 1.10); 0.97 (0.86, 1.09); 0.90 (0.79, 1.02); 0.86 (0.64, 1.16); 1.02 (0.92, 1.12); 1.00 (0.75, 1.33); 1.05 (0.95, 1.16); 1.07 (0.93, 1.24); 1.01 (0.90, 1.14); 1.01 (0.88, 1.15); 1.00 (0.88, 1.14). A table shows the number of events and percentages for tirzepatide and semaglutide in each subgroup.Abbreviations: BMI, body mass index; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio. Risk of asthma exacerbation between tirzepatide and semaglutide among patients with asthma and type 2 diabetes in the matched cohorts (subgroup analyses). As TriNetX is a real-time updating data platform, patient records are continuously updated with new medical encounters or changes in eligibility. Subgroup analyses involved filtering the original cohort (pre-matching) by subgroup criteria and then re-performing 1:1 propensity score matching, which may result in slight differences in patient numbers compared to the main analysis due to data updates at the time of each query. For the secondary outcomes, tirzepatide was associated with a lower risk of receiving SABA compared with semaglutide (HR, 0.92; 95% CI, 0.88–0.96). The risk of receiving systemic corticosteroids was similar between groups (HR, 1.01; 95% CI, 0.96–1.05) (Supplementary Table 5). Discussion In this multicenter retrospective cohort study, we observed no difference in the risk of asthma exacerbation between tirzepatide and semaglutide among patients with asthma and T2D. These findings were consistent across multiple sensitivity analyses, including alternative follow-up durations and washout periods for new-user definitions, supporting the robustness of our results. Although no difference in exacerbation risk was observed, tirzepatide was associated with a lower risk of SABA use compared with semaglutide. Evidence evaluating the comparative effects of dual GIP/GLP-1 RAs versus GLP-1 RAs alone on respiratory outcomes remains limited. While preclinical data suggest that incretin-based therapies may attenuate airway inflammation, our study extends this evidence by demonstrating that the dual agonist tirzepatide performs comparably to semaglutide regarding asthma exacerbation risk in real-world settings.9,10 Additionally, we observed that tirzepatide was associated with a lower risk of SABA prescription. This finding aligns with a study by Chen et al, which used the same data source to evaluate asthma-related complications among patients with asthma.15 In their subgroup analysis of patients with comorbid T2DM, tirzepatide use was associated with a lower risk of receiving anti-asthmatic bronchodilators.15 Collectively, these findings suggest that tirzepatide may reduce the need for bronchodilators among patients with asthma, both with and without T2DM, compared with semaglutide. Notably, while Chen et al included all patients with asthma receiving tirzepatide or semaglutide, our study specifically focused on individuals with comorbid T2D.15 By restricting our cohort to this population, we minimized confounding by indication, as evaluating antidiabetic agents in a mixed population could introduce bias due to differences in baseline risk profiles and therapeutic goals. Obesity and poor glycemic control are well-established contributors to worse asthma control and an increased risk of exacerbation.4–8 Although tirzepatide has demonstrated greater effectiveness in weight reduction and glycemic control compared with GLP-1 RAs, these advantages did not translate into a differential reduction in asthma exacerbations in our study.12–14 It is possible that the magnitude of metabolic improvement achieved during the one-year follow-up period was insufficient to meaningfully influence exacerbation risk. We observed no difference in asthma exacerbation risk between the two groups across subgroups stratified by baseline BMI or HbA1c levels. Similarly, results remained consistent regardless of baseline prednisone use or a history of prior asthma exacerbations. However, because formal tests for interaction were not performed, we could not determine whether the treatment effect differed across subgroups. In addition, results were consistent across subgroups by the comorbid HF or CKD. Although GLP-1 RAs may confer cardiovascular and renal benefits in patients with HF or CKD, the risk of asthma exacerbation remained similar between treatment groups within these subpopulations.11 Nevertheless, disentangling the extent to which the observed outcomes are mediated by weight loss, glycemic control, or other biological pathways remains complex.9,10 The mechanisms underlying the respiratory effects of these incretin-based therapies still require further investigation. This study has several strengths. First, it leveraged a US multicenter database with a large sample size, enhancing generalizability and national representativeness.17 Second, the use of EHR data enabled adjustments for clinically relevant variables, such as BMI and HbA1c, which were often unavailable in studies using administrative claims data. Third, the new-user and active-comparator design minimized bias related to prevalent users, ensuring a robust comparison. Finally, the consistency of findings across multiple sensitivity and subgroup analyses supported the robustness of our results. However, there are some limitations to this study. First, residual confounding might exist, such as treatment adherence, socioeconomic status, calendar year, and prior exacerbation history. Additionally, direct measures of asthma severity were unavailable in TriNetX. Although we adjusted for baseline asthma medication use and performed subgroup analyses according to baseline prednisone use and history of asthma exacerbation, these measures may not fully capture asthma severity. Second, exposure was defined based on prescription data, which might not fully reflect actual medication use. Third, the exposure definition followed an intention-to-treat design and did not account for treatment switching or discontinuation. Because patients remained in their original exposure group regardless of subsequent treatment changes, exposure misclassification may have influenced the estimated associations; however, the direction and magnitude of any resulting bias cannot be determined from the available data. Due to data limitations in TriNetX, we were unable to conduct per-protocol analyses. Previous studies have reported switching or discontinuation rates of GLP-1 RAs or tirzepatide ranging from 23% to 50% across different follow-up periods and patient populations; therefore, future studies incorporating per-protocol analyses are needed to address this potential bias.21–23 Fourth, asthma exacerbations were identified using ICD-10 codes, which might lead to misclassification, as outpatient visits coded for asthma exacerbations could reflect other reasons for care. We were also unable to distinguish exacerbation severity. While composite definitions, such as combining systemic corticosteroid use with asthma-related hospitalizations, were unavailable in TriNetX, we adopted an ICD-10 code–based definition used in previous asthma studies conducted using this database.24–26 Additionally, the observed exacerbation rates were comparable to those reported in prior research.8,27 Lastly, many patients with missing BMI or HbA1c were excluded because these variables were considered important confounders.6,7,28 This complete-case approach may have introduced selection bias, particularly if missingness was associated with patient characteristics or outcomes. Alternative approaches to address missing data, such as multiple imputations, were not available within the TriNetX analytic platform. Future studies using data sources that permit more comprehensive approaches to missing data are needed to confirm our findings. Conclusion No difference in the risk of asthma exacerbation between tirzepatide and semaglutide was observed among patients with asthma and T2D. Given the observational design and the potential for residual confounding and outcome misclassification, these findings should be interpreted cautiously. Further investigation through randomized controlled trials is warranted to e clarify the comparative effects of these therapies on asthma outcomes.